Connected profiles1
Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Age Related Macular Degeneration (ARMD) peptide trials
1 selected ClinicalTrials.gov records carrying the official condition label Age Related Macular Degeneration (ARMD). The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
1 selected records.
Connected peptides
1 profiles.
Registry update years
2026–2026 in selected records.
Indication intelligence
Selected evidence landscape
Trial phases1
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 3 (1)
Registry statuses1
Overall statuses at each retained observation, not necessarily current today.
Active, not recruiting (1)
Across the connected peptide profiles, PeptideScanner also carries 38 selected PubMed records and 0 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Age Related Macular Degeneration (ARMD) unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT06373731
PeptideScanner retained ClinicalTrials.gov record NCT06373731 at 2026-07-30T16:19:36.914Z. Its registry update date was 2026-05-20, and PeptideScanner's reviewed identity mapping was elamipretide.
- PeptideScanner change date
- August 14, 2026
- Cited source date
- May 20, 2026
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Elamipretide · 2026-05-20
ClinicalTrials.gov record NCT06373731
Active, not recruiting at the retained observation.
Open attributed record →